A Study of MET233 in Individuals With Obesity or Overweight

Last updated: February 25, 2026
Sponsor: Metsera, a wholly owned subsidiary of Pfizer
Overall Status: Active - Not Recruiting

Phase

1/2

Condition

Obesity

Diabetes Prevention

Hypertriglyceridemia

Treatment

Placebo

MET233

Clinical Study ID

NCT07022977
MET233-24-101
C6501001
  • Ages 18-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity.

The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET233 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET233 or placebo. In Part C, participants will receive once-weekly doses of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy.

Exclusion

Exclusion Criteria:

  • Female who is lactating or who is pregnant according to the pregnancy test at theScreening visit or prior to the first study drug administration

  • Seated blood pressure higher than 160/95 mmHg at the Screening visit

  • Elevated resting pulse greater than 100 beats per minute at Screening visit

  • Presence of clinically significant ECG abnormalities

  • Diagnosis of diabetes (type 1 or type 2)

  • Participation in a weight loss program with or without pharmacotherapy during the 3months prior to study administration

  • Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosedmonogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiencyor Prader-Willi Syndrome).

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1/2
Study Start date:
November 20, 2024
Estimated Completion Date:
April 15, 2026

Study Description

This is a randomized, placebo-controlled, double-blind study designed to investigate the safety, tolerability, PK and pharmacodynamic (PD) of single and multiple ascending subcutaneous (SC) doses of MET233 in otherwise healthy adult participants with obesity or overweight (body mass index [BMI] 27.0 kg/m2 to 38.0 kg/m2, inclusive).

In Part A, approximately 40 participants will receive a single dose of MET233 at up to 5 dose levels. In Part B, approximately 40 participants will receive five weekly doses of MET233 at up to 4 dose levels. In Part C, up to 4 cohorts of 10 participants each will receive 12 weekly doses. These doses may include titration. For all cohorts in Part C, the 13th dose of MET233 administered on Day 85 may be a monthly-equivalent dose to allow evaluation of a potential to switch to a monthly dosing regimen.

Connect with a study center

  • MET233 Research Site 001

    Cypress, California 90630
    United States

    Site Not Available

  • MET233 Research Site 001

    Cypress 5341256, California 5332921 90630
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.